Epigenomics AG
· ISIN: DE000A37FT41
· EQS - Company News
Executive Board member Jens Ravens leaves the Company on April 30, 2024
Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor
Smart tools for smart investors can be found in our Tools section
Corporate News Epigenomics AG
In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
This might be interesting for you as well
30 April 2024 03:00PM
Executive Board member Jens Ravens leaves the Company on April 30, 2024
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a...
Epigenomics AG
30 April 2024 03:00PM
Executive Board member Jens Ravens leaves the Company on April 30, 2024
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024
Berlin (Germany), April 30, 2024 - Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024 due to the successful transfer of nearly all a...
Epigenomics AG
14 March 2024 08:00AM
Epigenomics AG publishes financial results for fiscal year 2023
Epigenomics AG publishes financial results for fiscal year 2023
Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
OPERATIONAL DEVELOPMENTS
Due to the lack of necessary financing for the further development of the Epi proColon “Next-Gen” test and t...
Epigenomics AG
15 February 2024 10:00AM
Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Bo...
Epigenomics AG
31 January 2024 03:30PM
Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
Berlin, January 31, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the "Company"), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that the Supervisory ...
Epigenomics AG
26 January 2024 01:16PM
Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)
Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)
Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024. The...
Epigenomics AG
More Epigenomics AG related information
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Corporate Research | 0 | - | - | Corporate Research |
| Directors Dealings | 0 | - | - | DD |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.
v.07062023 EN